Compare OSK & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSK | PODD |
|---|---|---|
| Founded | 1917 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 10.3B |
| IPO Year | 2009 | 2007 |
| Metric | OSK | PODD |
|---|---|---|
| Price | $140.44 | $144.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | $166.79 | ★ $341.48 |
| AVG Volume (30 Days) | 649.7K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.14 | ★ 1.30 |
| Revenue | ★ $7,705,500,000.00 | $2,708,100,000.00 |
| Revenue This Year | $5.94 | $24.55 |
| Revenue Next Year | $7.19 | $19.18 |
| P/E Ratio | $120.81 | ★ $110.06 |
| Revenue Growth | 12.83 | ★ 30.73 |
| 52 Week Low | $108.30 | $140.63 |
| 52 Week High | $180.49 | $354.88 |
| Indicator | OSK | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 39.29 |
| Support Level | $137.69 | $143.11 |
| Resistance Level | $158.99 | $161.35 |
| Average True Range (ATR) | 4.30 | 6.16 |
| MACD | 1.70 | 0.90 |
| Stochastic Oscillator | 87.18 | 14.97 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.